Endo, Inc. (NDOI)
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenues, net | 392,833,000 | 426,506,000 | - | |
| Research and development | 31,634,000 | 20,190,000 | - | |
| Acquired in-process research and development | 2,536,000 | 1,750,000 | - | |
| Other expense, net | -1,028,000 | 1,193,000 | - | |
| Interest expense, net | -52,670,000 | -62,727,000 | - | |
| Litigation-related and other contingencies, net | -320,000 | -200,000 | - | |
| Cost of revenues | 295,403,000 | 448,324,000 | - | |
| Acquisition-related and integration items, net | 1,015,000 | 1,773,000 | - | |
| Selling, general and administrative | 149,041,000 | 148,322,000 | - | |
| Loss from continuing operations before income tax | -140,814,000 | -255,587,000 | - | |
| Income tax (benefit) expense | -12,184,000 | -22,811,000 | - | |
| Loss from continuing operations | -128,630,000 | -232,776,000 | - | |
| Net loss | -128,630,000 | -232,776,000 | -148,776,000 | |
| Basic eps | -1.69 | -3.06 | - | |
| Diluted eps | -1.69 | -3.06 | - | |
| Basic average shares | 76,211,000 | 76,156,000 | - | |
| Diluted average shares | 76,211,000 | 76,156,000 | - | |